Education
About Us
Working with TipRanks
Follow Us
Genfit SA (GNFT)
NASDAQ:GNFT
GNFT Stock Chart & Stats
Day’s Range― - ―
52-Week Range$3.11 - $6.42
Previous CloseN/A
Volume1.39K
Average Volume (3M)8.09K
Market Cap
$182.95M
Enterprise Value$224.50M
Total Cash (Recent Filing)€13.94M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)7.6
Beta0.56
Next Earnings
Apr 24, 2025EPS Estimate
-0.26Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.48
Shares Outstanding49,996,185
10 Day Avg. Volume4,786
30 Day Avg. Volume8,092
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)5.80
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$13.00Price Target Upside254.22% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
---
Genfit SA News
PremiumCompany Announcements
GENFIT Secures €185 Million Royalty Financing to Boost Liver Disease Research
PremiumCompany Announcements
GENFIT Secures Bondholder Approval for 2025 OCEANEs Amendments
PremiumCompany Announcements
GENFIT Reports Strong 2024 Financial Results and Secures Future Funding
PremiumCompany Announcements
GENFIT Advances 2025 OCEANEs Repurchase with Key Agreements
PremiumCompany Announcements
GENFIT Amends Terms of 2025 OCEANEs Proposal Amid Royalty FinancingPremiumCompany Announcements
GENFIT Finalizes 2025 Bond Repurchase Terms Amidst Royalty Financing Deal---
Bulls Say, Bears Say
Bulls Say
Financial StabilityGENFIT entered into a royalty financing agreement with HealthCare Royalty (HCRx) for up to €185M in total funding, providing financial stability and resources for future projects.
Regulatory ApprovalsIqirvo received FDA approval for the treatment of 2L primary biliary cholangitis (PBC), along with a positive opinion from the Committee for Medicinal Products for Human Use (CHMP), setting the stage for a strong commercial launch.
Bears Say
Debt ManagementPlans to eliminate outstanding convertible debt should provide further capital flexibility for the company moving forward, but could also indicate challenges in financial management.
Regulatory RisksKey risks to the rating and price target include potential delays in clinical and regulatory timelines and failure to obtain regulatory approvals in additional markets.
---
Ownership Overview
―
Insiders
<0.01% Mutual Funds
<0.01% Other Institutional Investors
99.94% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
GNFT FAQ
What was Genfit SA’s price range in the past 12 months?
Genfit SA lowest stock price was $3.11 and its highest was $6.42 in the past 12 months.
What is Genfit SA’s market cap?
Genfit SA’s market cap is $182.95M.
When is Genfit SA’s upcoming earnings report date?
Genfit SA’s upcoming earnings report date is Apr 24, 2025 which is in 23 days.
How were Genfit SA’s earnings last quarter?
Genfit SA released its earnings results on Sep 19, 2024. The company reported $0.591 earnings per share for the quarter, beating the consensus estimate of $0.337 by $0.254.
Is Genfit SA overvalued?
According to Wall Street analysts Genfit SA’s price is currently Undervalued.
Does Genfit SA pay dividends?
Genfit SA does not currently pay dividends.
What is Genfit SA’s EPS estimate?
Genfit SA’s EPS estimate is -0.26.
How many shares outstanding does Genfit SA have?
Genfit SA has 49,996,185 shares outstanding.
What happened to Genfit SA’s price movement after its last earnings report?
Genfit SA reported an EPS of $0.591 in its last earnings report, beating expectations of $0.337. Following the earnings report the stock price went up 15.513%.
Which hedge fund is a major shareholder of Genfit SA?
Currently, no hedge funds are holding shares in GNFT
---
Genfit SA Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$13.00 (254.22% Upside)
$13.00 (254.22% Upside)
Blogger Sentiment
Bullish
GNFT Sentiment 100%
Sector Average 69%
Sector Average 69%
Crowd Wisdom
Negative
Last 7 Days ▼ 1.5%
Last 30 Days ▲ 0.2%
Last 30 Days ▲ 0.2%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
3.08%
12-Months-Change
Fundamentals
Return on Equity
26.13%
Trailing 12-Months
Asset Growth
-1.36%
Trailing 12-Months
Company Description
Genfit SA
Genfit S.A., a biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company's products include Elafibranor, which is in Phase 3 clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; GNS561, which is in Phase 1b/2 trial to treat patients with cholangiocarcinoma (CCA); and Nitazoxanide, which is in Phase 1 trial to treat acute-on-chronic liver failure. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and with Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. Genfit S.A. was incorporated in 1999 and is headquartered in Loos, France.
---
GNFT Stock 12 Month Forecast
Average Price Target
$13.00
▲(254.22% Upside)
Technical Analysis
Amarin
―
Sangamo Biosciences
―
Innate Pharma
―
Foghorn Therapeutics
―
Inhibikase Therapeutics
―
Best Analysts Covering GNFT
1 Year
1 Year Success Rate
6/17 ratings generated profit
1 Year Average Return
-5.58%
reiterated a buy rating 2 months ago
Copying Ed Arce's trades and holding each position for 1 Year would result in 35.29% of your transactions generating a profit, with an average return of -5.58% per trade.
---